Company: Deciphera Pharmaceuticals
Based: Lawrence, KA
Investor: Kansas Technology Enterprise Corporation
Scoop: Deciphera Pharmaceuticals is developing drugs to attack the molecular cause of Alzheimer's disease, rheumatoid arthritis, asthma and other diseases. The company has two programs. DCC-2036 is a bcr-Abl inhibitor now in preclinical development for the management of treatment-resistant or intolerant chronic myeloid leukemia. Deciphera has recently applied its unique approach to kinase inhibitor design to B-Raf kinase. It is also pursuing two strategies centered on B-Raf inhibition.